In the United States, is the Signatera (personalized circulating tumor DNA) assay used to monitor breast cancer?

Signatera ctDNA Testing for Breast Cancer Monitoring in the United States

Signatera (personalized circulating tumor DNA) testing is not part of standard breast cancer surveillance guidelines in the United States, but emerging evidence supports its use in high-risk patients for early detection of molecular recurrence, particularly in those with advanced stage disease or nodal involvement.

Current Guideline-Based Surveillance

The ACR Appropriateness Criteria 1 for breast cancer monitoring do not include ctDNA testing. Standard surveillance relies on:

• Mammography/Digital Breast Tomosynthesis (rated 7-9 for appropriateness)
• Breast ultrasound (rated 8-9)
• MRI with contrast (rated 9 for post-neoadjuvant monitoring)

These imaging modalities remain the guideline-recommended approach for monitoring breast cancer patients.

Emerging Role of Signatera ctDNA Testing

Despite absence from formal guidelines, recent high-quality research demonstrates compelling clinical utility:

Detection Performance

Signatera shows 88.2% sensitivity for detecting recurrence before clinical or radiologic evidence 2, with lead times up to 38 months (median 10.5 months). In high-risk patients specifically, sensitivity reaches 88.89% with 97.37% specificity 3.

Optimal Patient Selection

ctDNA testing appears most valuable in:

• Advanced pathologic stage with nodal involvement 4 - where 4.41% of monitored patients showed detectable ctDNA
• Triple-negative breast cancer - all relapsing patients (7/7) had positive ctDNA within median 8 months 2
• High-risk stage I-III disease - where 14% showed detectable ctDNA during surveillance 3

Clinical Management Based on ctDNA Results

When ctDNA is detected 4:

1. Obtain PET imaging for metastatic workup
2. If imaging positive → initiate systemic therapy
3. If imaging initially negative → repeat ctDNA in 6 months with interval imaging
4. Rising ctDNA values warrant repeat imaging even if initially negative

When ctDNA is negative:

• 97% overall survival at 6 months, approximately 90% at 12 months 5
• Provides strong reassurance for patients 2

Important Caveats

Hormone receptor-positive (HR+) disease requires caution: Five of 122 non-relapsed HR+ patients had occasional positive tests 2, and all four false-negative cases before relapse had HR+ disease. Serial monitoring is essential in HR+ patients rather than acting on single positive results.

Post-operative timing matters: ctDNA detection after surgery but before adjuvant therapy identifies molecular residual disease with hazard ratio of 5.5 for distant recurrence 6, with median lead time of 16 months before clinical relapse.

Practical Implementation Algorithm

For high-risk breast cancer patients (stage II-III, node-positive, or triple-negative):

1. Establish baseline: Obtain ctDNA 1-14 weeks post-operatively before adjuvant therapy
2. Serial monitoring: Test every 6 months during surveillance
3. If positive: PET imaging → treat if metastases found → repeat ctDNA in 6 months if imaging negative
4. If negative: Continue standard surveillance with reassurance
5. For HR+ disease: Require 2+ consecutive positive tests or rising values before intervention

The evidence strongly supports ctDNA testing in high-risk patients as an adjunct to—not replacement for—standard imaging surveillance, particularly given the 5.3-month average lead time for detecting recurrence 3 and strong prognostic value for both relapse-free and overall survival 2.